DHEA Pioneers CHR to Collaborate with University of Rochester School of Medicine and Dentistry

0
Posted by Marie on May 10, 2012 at 9:33 am

May 10, 2012 (New York, NY) – The Center for Human Reproduction (CHR), a prominent New York City-based clinical CHRand research center specializing in female and male infertility treatment, announced a research collaboration agreement with the University of Rochester School of Medicine and Dentistry (URSMD) to commence on July 1st, 2012. This collaborative effort between investigators at URSMD and CHR aims to combine two institutions with strong common interests and expertise in exploring the process of follicle maturation, and especially the role of androgens in female reproduction.

Lead investigators are Aritro Sen, PhD, Research Assistant Professor, and Stephen R. Hammes, MD, PhD, Professor, both in the Division of Endocrinology and Metabolism at URSMD and who have published pioneering work on the subject in a rodent model; and Norbert Gleicher, MD, CHR’s Chief Scientist, and David H. Barad, MD, MS, Senior Scientist at CHR, who by introducing the androgen dehydroepiandrosterone (DHEA) into infertility treatment have revolutionized the treatment of women with low ovarian reserve worldwide.

“The goal of this research collaboration is to combine complementary animal and laboratory expertise at URSMD with clinical expertise at CHR,” explains Dr. Gleicher. “By combining research in URSMD’s unique animal model and CHR’s large clinical human experience, we aim to better understand how DHEA, as well as other androgens, improves female fertility.”

“This is a very exciting development,” adds Dr. Barad. “We have known for years now that DHEA improves pregnancy chances but only very recently learned that this very likely occurs through conversion of DHEA to testosterone. For all practical purposes, this means that the process very likely involves the androgen receptor (AR) on granulosa cells.” Dr. Barad continues: “For this kind of work, our colleagues at URSMD have the ideal mouse model.”

Dr. Sen, who will become a Visiting Assistant Scientist at CHR, chimes in: “we are very much looking forward to this collaboration, which should be very beneficial for both institutions.”

 

About Center for Human Reproduction
Center for Human Reproduction (CHR, http://www.centerforhumanreprod.com) is a leading fertility center in New York City with a worldwide reputation as a “fertility center of last resort,” offering cutting-edge, research-based treatment options to infertility patients. CHR introduced DHEA supplementation into infertility care in 2004. Dr. Gleicher, Dr. Barad and Dr. Sen are available for additional comments.

Posted in: Infertility
Tags: ,

Continue Reading

FERTINATAL™, the Much-Anticipated First DHEA Supplement for Female Fertility, Hits the Market

0
Posted by Marie on April 13, 2012 at 10:38 am

FertinatalApril 13, 2012 (New York, NY) – FERTINATAL™, the first and only dehydroepiandrosterone (DHEA) nutritional supplement designed to enhance female fertility, has entered the market today.

The launch took longer than expected, because Fertility Nutraceuticals, LLC – which developed the supplement – made unusual efforts to ensure that FERTINATAL™ DHEA for women would fulfill all of the required specifications which the product was designed for, with consistency across every tablet, according to Fertility Nutraceuticals. The required repeat rounds of quality-assurance testing at independent laboratories delayed the launch, initially scheduled for January.

“It was extremely frustrating, especially since we have seen increasing demand since we announced FERTINATAL last December,” notes Yu Kizawa, the company’s Director of Marketing and Sales. “Now, we are excited to be able to offer probably the most reliable micronized DHEA product on the market, and the only one specifically designed for women who have a difficult time conceiving.”

FERTINATAL™ was developed with strict adherence to the specifications of the Center for Human Reproduction (CHR, http://www.centerforhumanreprod.com), a research-driven fertility center in New York City that introduced DHEA supplementation for women with diminished ovarian reserve. Because of the high quality standard of FERTINATAL™, CHR, the only holder of female fertility-related U.S. patents for DHEA supplementation, endorses FERTINATAL™.

“Over-the-counter DHEA products can be very inconsistent in quality, even within the same brand,” explains Norbert Gleicher, MD, medical director of CHR. “Based on the unique quality control process of FERTINATAL™, we are confident that this new product will deliver the kind of consistency and quality we, up to this point, have been able to achieve only through pharmacy-compounded DHEA by prescription.  We, therefore, feel confident in endorsing FERTINATAL™.”

FERTINATAL™ is available for purchase at $69.50 per box (a one-month supply), online at http://www.fertinatal.com.

 

About Fertility Nutraceuticals, LLC
Fertiltiy Nutraceuticals, LLC, is a company specializing in nutritional supplements for women in reproductive years. The company is dedicated to developing highest-quality nutritional supplements for women with fertility problems, trying to achieve healthy pregnancies. FERTINATAL™ is the company’s first product, with additional products planned for rollout throughout 2012.

Posted in: DHEA, Fertility, Infertility, Pregnancy in Older Women
Tags: ,

Continue Reading

Efficacy of “Mini IVF” Under Question, New Study at Center for Human Reproduction Reveals

0
Posted by Marie on April 4, 2012 at 2:13 pm

CHRApril 4, 2012 (New York, NY) —A new study by New York’s Center for Human Reproduction (CHR) has cast doubts on the efficacy of low intensity IVF (LI-IVF) programs, marketed under various names like “mini IVF” and “natural IVF.” According to the study, LI-IVF programs, which utilize lower doses of fertility medications to reduce costs and monitoring visits, do not live up to their proponents’ claims of pregnancy rates comparable to those in conventional low cost IVF.

To evaluate the claims that LI-IVF is more economical and more “patient-friendly,” researchers at CHR matched patients in LI-IVF cycles to comparable patients undergoing traditional IVF cycles. In the resulting study, just published online in the medical journal Reproductive Biomedicine Online1, patients in LI-IVF cycles produced significantly fewer oocytes and embryos, and faced much lower pregnancy rates. Lower pregnancy rates for LI-IVF patients were observed both in initial IVF cycles and cumulatively, taking account of subsequent transfers of cryopreserved embryos.

Most surprisingly, however, when overall costs to achieve a pregnancy were compared, highly touted “cost savings” with LI-IVF were nowhere to be observed. Lower pregnancy rates associated with LI-IVF meant that LI-IVF patients on average needed more cycles to have a take-home baby, which meant the lower per-cycle cost of LI-IVF did not translate into lower cost to achieve a successful pregnancy and delivery. Patients in LI-IVF cycles also took longer to conceive.

“LI-IVF appears to reduce pregnancy chances and prolong time to conception without offering any appreciable compensatory financial benefits,” summarizes Norbert Gleicher, MD, the study’s lead author and medical director of CHR. “When patients started asking for LI-IVF at our center, we, like many other IVF centers, decided to offer the procedure. In contrast to other centers, we, however, explained to our patients that LI-IVF should still be considered ‘experimental’ since no data existed, that compared this method of IVF to standard IVF.”

CHR required that patients sign “experimental” informed consents, and started accumulating outcome data.  Dr. Gleicher now notes: “As the result of our study well demonstrates, doing otherwise would have been rather unethical.”

“We must caution patients against resorting to ‘mini IVF’ or ‘natural IVF’ without carefully weighing their options,” warns David Barad, MD, another author of the study and director of clinical ART at CHR. “Until more data becomes available, physicians should offer LI-IVF only as an experimental procedure.”

1Gleicher N et al., A case-control pilot study of low-intensity IVF in good-prognosis patients. Reprod Biomed Online 2012; In press. [Epub ahead of print].

 

About Center for Human Reproduction
Center for Human Reproduction (CHR, http://www.centerforhumanreprod.com) is a leading fertility center in New York City with a worldwide reputation as a “fertility center of last resort,” offering cutting-edge, research-based treatment options to patients with even the most complex cases of infertility. Dr. Gleicher and Dr. Barad are available for additional comments.

Posted in: Infertility, IVF
Tags: ,

Continue Reading

New Genetic Test Predicts Better Egg Production for Women with Poor Ovarian Reserve, Study Shows

0
Posted by Marie on March 19, 2012 at 9:05 am

March 19, 2012 (New York, NY) – A genotype of the FMR1 (fragile X mental retardation) gene preserves a woman’s ability to produceCHR eggs (oocytes) well into the 40s, according to an ovarian aging study just published in the medical journal PLoS One1.

Conducted at the Center for Human Reproduction (CHR), a fertility center in New York City specializing in fertility treatments for older women, the study compared egg yields during in vitro fertilization (IVF) in women above age 40 with varying FMR1 genotypes and sub-genotypes.

In women with very poor ovarian reserve (i.e., women with the poorest ovarian function), the FMR1 sub-genotype het-norm/high (normal CGG repeat count on one allele, abnormally high count on the other) produced significantly more eggs than other genotypes and sub-genotypes. This observation suggests that the het-norm/high FMR1 sub-genotype preserves a woman’s ability to produce a good number of eggs at older ages even if the ovarian reserve is severely reduced.

“From our previous research, we knew that the het-norm/high sub-genotype was responsible for slow recruitment of eggs into maturation process at younger ages than other genotypes and sub-genotypes,” explains Norbert Gleicher, MD, lead author of the study and Medical Director of CHR. “Because these women ‘use up’ fewer eggs from their egg reserve, we suspected that they may have more eggs left when older. This study confirmed this hypothesis, demonstrating that women with this sub-genotype performed better in IVF cycles than even women with normal FMR1 genotype.”

These findings further enhance the understanding of genetic control over the process of ovarian aging, and further refine prognostication in older women undergoing fertility treatments. Given that oocyte yields in IVF cycles usually correlate with pregnancy chances, older women with extremely low ovarian reserve, therefore, appear to have better chances of success if their FMR1 sub-genotype is het-norm/high.

 

1Gleicher N et al. The impact in older women of ovarian FMR1 genotypes and sub-genotypes on ovarian reserve. PLoS One 2012:e33638. [http://dx.plos.org/10.1371/journal.pone.0033638]

 

About Center for Human Reproduction

Center for Human Reproduction, or CHR (http://www.centerforhumanreprod.com), is a leading fertility center in the United States with a worldwide reputation as a “fertility center of last resort,” specializing in treatment of infertility in women with diminished ovarian reserve, including younger women with premature ovarian aging (POA) and older women with physiological ovarian aging. Dr. Gleicher is available for additional comments.

Posted in: Pregnancy in Older Women
Tags: ,

Continue Reading

Diminished Ovarian Reserve Expert Releases Tip Sheet for Timely Infertility Diagnosis for Young Women

0
Posted by Marie on March 7, 2012 at 10:50 am

March 07, 2012 (New York, NY) – Center for Human Reproduction (CHR), a leading New York fertility center specializing in fertility CHRtreatment for women with diminished ovarian reserve (DOR), has issued a fertility tip sheet for young women with DOR. Younger women with DOR often spend months or even years before receiving the correct diagnosis, resulting in significant delays in appropriate fertility treatments.

“Detecting DOR is not difficult,” says Dr. Gleicher, Medical Director and Chief Scientist of CHR. He continues: “Ovarian reserve can be easily measured by simple blood tests, like follicle-stimulating hormone (FSH) and anti-Müllerian hormone (AMH).  High FSH and/or low AMH suggest a diagnosis of DOR but both need to be assessed in an age-specific way.”

However, many fertility centers, unused to treating younger women with premature ovarian aging (POA; a term coined by CHR to describe younger women with DOR), often overlook this condition. “They overlook the diagnosis,” explains Dr. Gleicher, “because they do not utilize age-specific cut off values for FSH and AMH.”

Normal FSH ranges increase and normal AMH ranges decrease as women age.  If all women of all ages are assessed with universal cutoff values, younger women will never be diagnosed in timely fashion. “Unfortunately,” says Dr. Gleicher, “this is what is still done in many fertility centers.”

Once diagnosed with POA, like older women, women with POA have little time to lose since there is no telling how quickly their POA will progress. Though very rapid progression is rare, according to Dr. Gleicher, CHR physicians have seen women go into full menopause in a few short months after diagnosis.

Dr. Gleicher continues: “There isn’t a day when we don’t hear our patients say ‘doctor, I wish I’d known about your center months ago, when I was doing such and such…’ The earlier we can start treatment, the better, of course, our chances of helping our patients with POA!”

CHR’s tips for younger women with POA to receive timely diagnosis and treatment include the following:

  • Be very skeptical of the pseudo-diagnosis of “unexplained infertility.” Especially in younger women, this diagnosis only means that a diagnosis of POA was missed.
  • Insist on age-specific ovarian reserve testing with FSH and AMH.
  • If your age-specific FSH and/or AMH values are abnormal before age 40, you likely suffer from POA.
  • If that is not clearly spelled out to you, your physician may have little experience with diagnosis and treatment of POA, and it may be time for a second opinion.
  • Remember that with a diagnosis of POA, time is crucial, because nobody can predict how quickly your ovarian reserve will further decline.

 

About Center for Human Reproduction

Center for Human Reproduction, or CHR, is a leading fertility center in the United States with a worldwide reputation as a “fertility center of last resort,” specializing in treatment of infertility in women with diminished ovarian reserve, including younger women with premature ovarian aging (POA) and older women with physiological ovarian aging. Dr. Gleicher is available for additional comments.

Posted in: Pregnancy in Older Women
Tags: ,

Continue Reading

Premature Ovarian Aging Expert Issues Fertility Tip Sheet for Women Interested in Pregnancy Over 40

0
Posted by Marie on March 1, 2012 at 3:37 pm

March 1, 2012 (New York, NY) – Center for Human Reproduction (CHR), a leading New York fertility center specializing in pregnancy CHRin older women, has issued a fertility tip sheet for women trying to get pregnant after age 40. With a growing number of women interested in pregnancy over 40, timely evaluation and diagnosis of infertility are becoming ever more important.  However, they remain elusive for many patients.

“It’s important to recognize the urgency of aggressive fertility treatment when you are above age 40,” says Dr. Gleicher, Medical Director of CHR, which released the tip sheet. As women get older, their ovarian reserve (a measure of ovaries’ ability to produce good-quality eggs) declines. Because this process of ovarian aging speeds up significantly after age 40, timely diagnosis of infertility becomes crucial especially after age 40. Every fertility treatment loses efficacy rapidly with declining ovarian reserve.

As a “fertility center of last resort” for patients with diminished ovarian reserve, CHR sees a large number of women over 40 with premature ovarian aging.  Dr. Gleicher continues: “There isn’t a day when we don’t hear our patients say ‘doctor, I wish I’d known about your center years ago, when I was doing such and such…’ The earlier we can start treatment, the better, of course, our chances of helping our patients! This is why we are issuing this fertility tip sheet.”

CHR’s fertility tips for women trying to get pregnant after 40 include:

  • Recognize the urgency of aggressive fertility treatment when you are above age 40.
  • Insist on rapid diagnosis and a structured treatment plan.
  • Insist on specific treatment goals that meet your expectations.  For example, do not agree to treatment with clomiphene citrate and intrauterine insemination (IUI) if the expected pregnancy chance sounds ridiculously low.
  • Do not agree to endless testing to “wait for the right results” – time is not on your side, and results will only get worse!
  • It never hurts to get a second opinion.

 

About Center for Human Reproduction

Center for Human Reproduction, or CHR (http://www.centerforhumanreprod.com), is a leading fertility center in the United States with a worldwide reputation as a “fertility center of last resort,” specializing in treatment of infertility in women with diminished ovarian reserve, including younger women with premature ovarian aging (POA) and older women with physiological ovarian aging. Dr. Gleicher is available for additional comments.

Posted in: Pregnancy in Older Women
Tags: ,

Continue Reading

European Nations Fall Behind US in IVF Pregnancy Rates

0
Posted by Marie on February 6, 2012 at 10:59 am

February 6, 2012 (New York, NY) – Recent reports of plateauing IVF pregnancy rates in Europe are in stark contrast to still-rising rates IVFin the US, according to Norbert Gleicher, M.D., a prominent fertility expert and Medical Director of the Center for Human Reproduction (CHR) in New York City. Behind this difference may be a fundamental difference in approaches to the patient-physician relationship in Europe and the US.

Focus on Reproduction, the official magazine of the European Society for Human Reproduction and Embryology (ESHRE), recently reported that in Europe overall IVF pregnancy rates have leveled off.

As first reported by Dr. Gleicher’s team in 2006(1,2), European IVF pregnancy rates are significantly lower than American rates.  The most recent European data show clinical pregnancy rate per cycle of 32.5%. Conservatively assuming a miscarriage rate of 15%, this would translate into delivery rates of 26.6%. During the same time period, the US delivery rate was 40.7%.

The question is why.

“A part of the reason is the recent propagation of single-embryo transfer (sET) in Europe,” explains Dr. Gleicher. “In Europe, fertility experts and governments alike consider the reduced risk of multiple pregnancies through sET a good enough reason to offset lower pregnancy chances caused by sET. Thus, many European countries mandate sET despite irrefutable evidence that patients value nothing more than better chances of pregnancy in choosing their infertility treatments.

“This is a good example for the fundamental difference in the socio-medical philosophy between Europe and the US,” points out Dr. Gleicher: “Europe values what they perceive as the ‘common good’ over individual rights of patients. What they fail to recognize, however, are the unintended consequences affecting the patient-physician relationship and, most importantly, IVF outcomes.”

He continues: “Not only do patients end up with much lower pregnancy chances with IVF than their U.S. counterparts, they, in the end, are also forced to undergo more IVF cycles , at more cost, and, of course, more risks.” Europe, therefore, performs more than three-times as many IVF cycles per capita than the US. The same philosophy in Europe also results in outright rationing. For example, most Scandinavian countries withhold all IVF treatment from women above age 40-41, an approach unthinkable in the US.

“If there is a lesson to be learned here,” says Dr. Gleicher, “it is that IVF pregnancy rates in the U.S. will continue to improve, as long as IVF research and clinical care remain largely unaffected by government interference, and primarily driven by success in the marketplace, as they have over the last few decades.”

 

(1)Gleicher et al. A formal comparison of the practice of assisted reproductive technologies between Europe and the USA. Hum Reprod 2006;21:1945-50; (2)Gleicher et al. Update on the comparison of assisted reproduction outcomes between Europe and the USA: the 2002 data Fertil Steril 2007;87:1301-5.

 

About Center for Human Reproduction

Center for Human Reproduction, or CHR, is a leading fertility center in the United States with a worldwide reputation as a “fertility center of last resort,” specializing in treatment of infertility in women with diminished ovarian reserve. Under the leadership of Dr. Norbert Gleicher, CHR has been helping many European patients—in addition to local New York and North American patients—receive state-of-the-art fertility treatments. Dr. Gleicher is available for additional comments.

Posted in: IVF
Tags: , ,

Continue Reading

Fertility Nutraceuticals, LLC Launches FERTINATAL Micronized DHEA Supplement for Enhanced Female Fertility

0
Posted by Marie on December 22, 2011 at 9:28 am

FertinatalDecember 22, 2011 (New York, NY) – Fertility Nutraceuticals, LLC – a company specializing in nutritional supplements for women and female fertility enhancement – is announcing the launch of FERTINATALTM micronized dehydroepiandrosterone (DHEA) supplement.  The high-quality DHEA supplement is designed to augment female fertility.

Intrigued by anecdotal evidence received from one of their patients, physicians at New York’s Center for Human Reproduction (CHR) – a leading fertility and research center – initiated research on the relationship between DHEA supplementation and enhanced female fertility.  Although research on the effects of DHEA is still limited, the published results of CHR’s studies are encouraging.

FERTINATALTM was developed to offer the public exactly the same kind of DHEA utilized by CHR in the center’s research studies.  The product features the highest quality control standards, including a triple-step testing process with batch-testing by independent laboratories.  Furthermore, FERTINATALTM is micronized to the same particle sizes as used in those studies. The product’s three-step testing process ensures that FERTINATALTM delivers on its three promises: a plant-derived DHEA product of highest quality, micronized to appropriate sizes for good absorption.

FERTINATAL™ is the first DHEA supplement exclusively designed for women and female fertility enhancement.  To improve convenience, it is uniquely packaged in individual blister sheets, each containing seven (7) rows of three (3) daily tablets, representing one week of the suggested supply of DHEA supplementation.  Each box of FERTINATALTM contains four of these blister sheets (a four-week supply).  FERTINATAL™ is not intended for individuals under the age of 18, and potential side effects are described on the product’s packaging.

FERTINATALTM will become available exclusively through Fertility Nutraceuticals, LLC in January 2012.

 

About Fertility Nutraceuticals, LLC
Fertility Nutraceuticals, LLC is a newly established company exclusively dedicated to nutritional supplements for women and enhanced female fertility.  FERTINATAL™ DHEA supplement is the company’s first product, with as many as 2-3 additional products expected to arrive throughout 2012.  For more information, visit http://www.fertinatal.com.

Posted in: DHEA, Miscarriage, Pregnancy in Older Women
Tags:

Continue Reading

New York Infertility Treatment Center Receives Second DHEA Patent Regarding Use in Female Infertility

0
Posted by Marie on December 20, 2011 at 9:25 am

CHRDecember 20, 2011 (New York, NY) – New York’s Center for Human Reproduction (CHR) is pleased to announce that the United States Patent and Trademark Office has approved a patent application for infertility treatment, serial number 8,067,400, titled “Androgen Treatments in Females.”

The claims of this allowed application – the second received based on CHR’s research of dehydroepiandrosterone (DHEA) in women with infertility – are directed to methods of decreasing aneuploidy rates (chromosomal abnormalities) in human embryos, decreasing time to pregnancy and increasing pregnancy rates by administering an androgen for at least two months.

In layman’s terms, this means that DHEA has been recognized (in this second patent issued to CHR) as an infertility treatment to increase pregnancy rates, reduce time to conception and reduce chromosomal abnormalities in embryos. DHEA is thus the first agent ever recognized to reduce chromosomal abnormalities in human embryos. Since approximately 85% of all human miscarriages are believed to be due to chromosomal abnormalities, DHEA can also be assumed to reduce miscarriage rates.

CHR investigators have already observed reductions in miscarriage risk after DHEA supplementation [Gleicher et al., Miscarriage rates after dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve: a case control study. Reprod Biol Endocrinol 2009;7:108].

“This second patent awarded to CHR only confirms the increasing importance of DHEA supplementation in female infertility, which we had the opportunity to observe through our research for over seven years,” notes Norbert Gleicher, MD, CHR’s Founder and Medical Director as well as one of the inventors listed on the DHEA patents.  He further points out that “acceptance of the claim that DHEA reduces chromosomal abnormalities in embryos offers exciting new opportunities because this observation suggests that DHEA supplementation may benefit not just women with infertility.”

Picking up on this thought, David H. Barad, MD – CHR’s Director of Clinical IVF and a second inventor listed on the patents – notes that “chromosomal abnormalities in embryos increase as women age. Therefore miscarriage rates rise in parallel. DHEA supplementation may, therefore, also be useful in older women with normal fertility who are trying to conceive on their own.” He adds that “the prenatal multivitamins of the future may also contain a little bit of DHEA.”

 

About CHR
Center for Human Reproduction (http://www.centerforhumanreprod.com) is a leading infertility center in New York City with worldwide clientele, well-recognized for its major clinical research program.  The program has contributed a number of essential breakthroughs to the IVF process. Dr. Gleicher is available for further comments.

Posted in: DHEA, Fertility, Pregnancy in Older Women
Tags: ,

Continue Reading

Healthcare Web Portal from Medical Web Experts Featured on New Social Website How2Connect.com

0
Posted by Marie on December 19, 2011 at 1:42 pm

MWEDecember 19, 2011 (San Diego, CA) – Healthcare web portal and medical web design agency Medical Web Experts is announcing their partnership with How2Connect.com – an online provider of therapeutic services that promotes health, wellness and community.  Medical Web Experts has developed a unique online patient web portal custom-built for wellness, and it will allow users to communicate securely with licensed clinicians as well as learn new techniques for improving their health.

“How2Connect.com’s groundbreaking approach to behavioral healthcare – paired with our advanced portal technology – is a perfect combination for effective healthcare delivery in the internet age,” says John Deutsch, CEO and founder of Medical Web Experts.

How2Connect.com is a new therapeutic and social networking site that allows users to connect and get behavioral health services all at affordable prices while using the anonymity of the internet.  Members are able to seek behavioral health therapy, explore questions in spirituality, and improve their health and wellness with advice from real medical professionals.  Users can use the site as a viable resource to improve their health and gain balance in their lives through the robust Wellness area, which features the Medical Web Experts Patient Portal.  Experienced in medical practice and hospital patient portal design, this new wellness portal will allow patients to log in over a secure, HIPAA-compatible connection and communicate directly with medical staff to ask questions and find new solutions to improve their health.

“We needed genuine experts to help us realize our vision and that is exactly what we found with the aptly named Medical Web Experts,” said Tracy Wood, President of How2Connect.com. “Bringing affordable therapeutic healthcare services plus a rich social networking experience to people who might otherwise not have access to what they really need is a tremendous reward in itself, but the frosting on the cake has been this collaboration with true professionals,” she said.

Selected due to its customizability and advanced medical records integration system, the portal also allows users communicate their health needs to their online wellness coach as well as incorporating online medical records.  The portal allows for video eConsultations and secure messaging with medical staff; Health Tracker software to keep track of vital signs or weight loss; interactive education resources and more.  Users of How2Connect.com will also enjoy weight loss help; men’s and women’s wellness resources; recipes and nutrition education; and spiritual guidance to help find both mental and physical balance in their lives.

“I see a tremendous amount of opportunity in this partnership,” adds Deutsch.  “Patients are putting additional importance on wellness and spiritual well-being as a form of preventive medicine.”  The Medical Web Experts Patient Portal helps How2Connect incorporate spiritual, social, mental and physical health and offers users a new way to enrich their lives through an interactive online community.

 

About How2Connect.com
How2Connect.com is an interactive online Behavioral health, wellness site and interactive site that offers users many ways to improve their spiritual, emotional and physical well-being with resources from medical professionals, therapists and a community of like-minded individuals.  Members can seek online therapy and health consultations, explore their spirituality, engage in the interactive portal, and create an “avatar” to interact in a virtual world with other How2Connect members.  The site launches in early 2012.  For more information, visit http://www.How2Connect.com.

About Medical Web Experts
A subsidy of New Wave Enterprises, LLC, Medical Web Experts offers healthcare web design for physician practices, hospitals, and all other healthcare organizations.  Their totally customizable Enterprise Patient Portal allows healthcare organizations of all types to incorporate a HIPAA-friendly login portal on their websites, improving their patients’ experience as well as boosting revenue and efficiency.  For more information, visit http://www.medicalwebexperts.com.

Posted in: Uncategorized
Tags: , ,

Continue Reading
1 2